Study wrapper · #37
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
Editor's note
This narrative review in the American Journal of Sports Medicine takes an appropriately cautious inventory of injectable peptide therapy for orthopaedic and sports medicine — a field where patient demand has outpaced clinical evidence considerably. The authors surveyed BPC-157, TB-4/TB-500, CJC-1295 plus ipamorelin, tesamorelin, and GHK-Cu via PubMed and found a consistent pattern: promising preclinical signals, thin or absent human data, and unresolved questions around dosing, frequency, and duration for every compound reviewed.
The review's conclusions align well with the broader evidence landscape for these peptides. BPC-157's lone human data point is a methodologically limited case series. Tesamorelin, the most regulation-hardened compound in the group with FDA approval and Phase III RCT backing, earned that standing for HIV-associated lipodystrophy — a narrow indication with no orthopaedic carryover. The murine muscle data for CJC-1295 plus ipamorelin is mechanistically interesting but cannot be extrapolated to clinical use.
As a narrative review, this paper synthesises existing literature rather than generating new data — it reflects the state of evidence rather than...
Plain-language abstract
Therapeutic peptides are short chains of amino acids that can influence various biological processes, and they have grown rapidly in popularity among patients seeking treatment for injuries or improved athletic performance. This narrative review, published in the American Journal of Sports Medicine, set out to summarise the current scientific evidence for injectable peptide therapies most commonly encountered in orthopaedic and sports medicine practice. Researchers conducted a comprehensive search of PubMed and evaluated six peptides: BPC-157, TB-4, TB-500, CJC-1295 combined with ipamorelin, tesamorelin, and GHK-Cu.
The review found that the evidence supporting clinical use of these peptides in orthopaedic settings is limited across the board. BPC-157 showed potential benefits for tendon and muscle repair in preclinical studies, but human evidence consists of a single small case series with significant methodological weaknesses. TB-4 and TB-500 showed tissue-repair and blood-vessel-growth effects in animal models, but human orthopaedic data are absent, and both are banned in competitive sport. CJC-1295 combined with ipamorelin improved a measure of muscle force in mice with medication-induced muscle loss, but this finding has not been studied in humans. Tesamorelin holds regulatory approval for a specific HIV-related condition but has no supporting orthopaedic evidence. GHK-Cu showed wound healing and anti-inflammatory signals in early research, but no clinical data...